The global healthcare landscape is currently witnessing a transformative shift in oncology, driven by a surge in precision medicine and early diagnostic breakthroughs. As of 2026, the market is characterized by a rapid transition from traditional "one-size-fits-all" chemotherapy toward highly personalized targeted therapies and immunotherapies. This strategic shift is reflected in the robust...